Garuti Laura, Roberti Marinella, Bottegoni Giovanni
Department of Pharmacy and Biotechnology, University of Bologna, via Belmeloro 6, I-40126 Bologna, Italy.
Curr Med Chem. 2015;22(6):695-712. doi: 10.2174/0929867321666141216125528.
The limitations of many mono-kinase inhibitors can be overcome by agents with multi-target action. An important advantage of targeting more than one kinase, is an increase in potency, due to the synergistic effect. Moreover, this approach can reduce the possibility of developing drug resistance. Several multitarget agents have been designed as single kinase inhibitors and found to be multi-target inhibitors because of the structural homology among the ATP-binding site of kinases. In other cases, these inhibitors have been obtained by optimization of potent individual inhibitors or by combination of selective ligands. Also some irreversible inhibitors act on different kinases and covalently modify the cysteine residues located near the ATP-binding pocket. In this review the most recent examples of multi-kinase inhibitors are reported, focusing on chemical structures, structure-activity relationship (SAR) and biological activity. These inhibitors, suitably substituted, could be used in designing other multitarget agents. Virtual molecular docking would suggest potential targets of molecules, moreover combining pharmacophore combination and screening methods could probably help in the discovery of more potent multikinase inhibitors.
许多单激酶抑制剂的局限性可以通过具有多靶点作用的药物来克服。靶向多种激酶的一个重要优势是,由于协同效应,其效力会增强。此外,这种方法可以降低产生耐药性的可能性。几种多靶点药物最初被设计为单激酶抑制剂,但由于激酶ATP结合位点之间的结构同源性,后来发现它们是多靶点抑制剂。在其他情况下,这些抑制剂是通过优化强效的单一抑制剂或通过组合选择性配体获得的。还有一些不可逆抑制剂作用于不同的激酶,并共价修饰位于ATP结合口袋附近的半胱氨酸残基。在这篇综述中,报道了多激酶抑制剂的最新实例,重点关注化学结构、构效关系(SAR)和生物活性。这些经过适当取代的抑制剂可用于设计其他多靶点药物。虚拟分子对接可以提示分子的潜在靶点,此外,结合药效团组合和筛选方法可能有助于发现更有效的多激酶抑制剂。